These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 2657749)
1. Polymorphism in drug design and delivery. Bernstein J Prog Clin Biol Res; 1989; 289():203-15. PubMed ID: 2657749 [No Abstract] [Full Text] [Related]
2. Solubility of molecular crystals: polymorphism in the light of solubility theory. Bennema P; van Eupen J; van der Wolf BM; Los JH; Meekes H Int J Pharm; 2008 Mar; 351(1-2):74-91. PubMed ID: 17980982 [TBL] [Abstract][Full Text] [Related]
3. A timely re-examination of drug polymorphism in pharmaceutical development and regulation. Grant DJ; Byrn SR Adv Drug Deliv Rev; 2004 Feb; 56(3):237-9. PubMed ID: 14962580 [No Abstract] [Full Text] [Related]
5. Applications of process analytical technology to crystallization processes. Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586 [TBL] [Abstract][Full Text] [Related]
6. Designing a molecular delivery system within a preclinical timeframe. Henck JO; Byrn SR Drug Discov Today; 2007 Mar; 12(5-6):189-99. PubMed ID: 17331883 [TBL] [Abstract][Full Text] [Related]
7. Automated approach to couple solubility with final pH and crystallinity for pharmaceutical discovery compounds. Seadeek C; Ando H; Bhattachar SN; Heimbach T; Sonnenberg JL; Blackburn AC J Pharm Biomed Anal; 2007 Apr; 43(5):1660-6. PubMed ID: 17270379 [TBL] [Abstract][Full Text] [Related]
8. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Thompson KH; Orvig C Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168 [TBL] [Abstract][Full Text] [Related]
9. Solid-state properties and crystallization behavior of PHA-739521 polymorphs. Sun CC Int J Pharm; 2006 Aug; 319(1-2):114-20. PubMed ID: 16720086 [TBL] [Abstract][Full Text] [Related]
10. The rational design of inhibitors of nitric oxide formation by inducible nitric oxide synthase. Whitlow M; Adler M; Davey D; Huang Q; Koovakkat S; Parkinson JF; Pham E; Polokoff M; Xu W; Yuan S; Phillips G Bioorg Med Chem Lett; 2007 May; 17(9):2505-8. PubMed ID: 17336523 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of soluble multivalent glycoconjugates that target the Hc region of botulinum neurotoxin A. Kale RR; Clancy CM; Vermillion RM; Johnson EA; Iyer SS Bioorg Med Chem Lett; 2007 May; 17(9):2459-64. PubMed ID: 17337184 [TBL] [Abstract][Full Text] [Related]
12. The role of cocrystals in pharmaceutical science. Shan N; Zaworotko MJ Drug Discov Today; 2008 May; 13(9-10):440-6. PubMed ID: 18468562 [TBL] [Abstract][Full Text] [Related]
13. A dodecalanthanide wheel supported by p-tert-butylsulfonylcalix[4]arene. Kajiwara T; Katagiri K; Takaishi S; Yamashita M; Iki N Chem Asian J; 2006 Sep; 1(3):349-51. PubMed ID: 17441070 [TBL] [Abstract][Full Text] [Related]
14. Thermodynamic inhibition profile of a cyclopentyl and a cyclohexyl derivative towards thrombin: the same but for different reasons. Gerlach C; Smolinski M; Steuber H; Sotriffer CA; Heine A; Hangauer DG; Klebe G Angew Chem Int Ed Engl; 2007; 46(44):8511-4. PubMed ID: 17902081 [No Abstract] [Full Text] [Related]
15. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Blagden N; de Matas M; Gavan PT; York P Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery. Bhattachar SN; Wesley JA; Seadeek C J Pharm Biomed Anal; 2006 Apr; 41(1):152-7. PubMed ID: 16364585 [TBL] [Abstract][Full Text] [Related]
17. Polymorph selection: the role of nucleation, crystal growth and molecular modeling. Erdemir D; Lee AY; Myerson AS Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526 [TBL] [Abstract][Full Text] [Related]